FACULTY
| Professor and Head | V.K.
Sharma |
| Professors | Neena Khanna |
| K.K. Verma | |
| Additional Professors | M. Ramam |
| Associate Professor | Binod K Khaitan |
| Assistant Professor | Sujay Khandpur |
| G. Sethuraman |
|
History |
CO 2 Laser
Postgraduates MD
Dermatology and Venereology
.
Achievements
of department
New inventive technologies introduced in our Institute
(i)
Innovative management of skin diseases
·
Pemphigus: Dexamethasone cyclophosamide pulse therapy
Oral betamethasone pulse
therapy
·
Collagen
vascular diseases: Dexamethasone pulse
therapy
Atopic dermatitis
·
Alopecia
areata: Treatment with
diphencyprone
300 mg oral prednisolone bolus
·
Mycetoma: 2 step treatment for mycetoma
(ii)
Innovations
Indian standard series for patch
testing
New investigative procedures introduced by your Institute
·
Touch,
pain & thermal sensation testing and grading devices, nasal filter
·
Dermograder
·
Cryostimulation
test
·
Complete diet
elimination for food allergy
·
A four
week therapeutic test for cutaneous TB
·
Titre of
contact hypersensitivity
·
Provocation
test for severe drug reactions
·
Aluminium
Patch Test Chambers
A Broad Band UV-B
in the treatment of Vitiligo
Seventeen patients (9 males, 8 females) between ages of 10
to 40 years were treated with
broad band UV-B twice a week by Waldmann’s UV
7001 K unit. Eleven patients received
25-44 (mean 33) exposure of UV-B over 4-6 months. Repigmentation was observed in
8
(72.7%) out of 11 patients and remaining 3 showed no response.
Repigmentation was
diffuse and to the extent of 10-25% only and none of the
patients had satisfactory cosmetic
improvement. It was concluded that broad band UV-B given twice a week over 4
months
was not effective in vitiligo.
A.
Role of contact allergens in the etiology of pompholyx.
B.
Natural history of parthenium dermatitis
C.
Hydroxyurea in the treatment of psoriasis
D.
Minodixil and betamethasone dipropionate combination in the
treatment of extensive
alopecia areata
E.
Diphencyclopropenone in the treatment of alopecia
universalis and totalis
F.
Identification of risk factors for extensive vitiligo
G.
Evaluation of the effficacy of intravenous cyclophosphamide
monthly pulse (15 mg/kg )
with daily oral prenisolone (1 mg/kg) in the therapy
of pemphigus.
H. Reproducibility
of patch test at upper back, lower back and forearm in patients with
parthenium
dermatitis.
I. Effectiveness
of CO2 laser in benign vascular lesions, epidermal and sebaceous nevi,
angiofibromas & keloids
J. Azathioprine as
a corticosteroid sparing
agent in the treatment of air borne
contact dermatitis.
K. To evaluate
the role of
immunosuppressive drugs for the treatment of chronic idiopathic
urticaria.
L. Long-term safety and toxicity of azathioprine
in patients of air-borne contact dermatitis.
M.
Evaluation of efficacy of fixed duration (12 weeks)
multidrug therapy with newer antileprosy
bactericidal drugs in multibacillary
leprosy.
N.
A comparative study of punch grafting followed by topical
conticosteroids vs punch grafting
followed by PUVA therapy in stable vitiligo.
O. Further evaluation of Dexamethasone Cyclophosphamide Pulse
therapy in pemphigus.
P.
Evaluation of punch grafting in halo naevi with/without
limited vitiligo.
A.
Evaluation of PCR in the diagnosis of cutaneous tuberculosis
(Microbiology, Pathology
and Biostatistics).
The laboratory diagnosis of
tuberculosis rests on the direct demonstration of Mycobacterium
tuberculosis in
smears or biopsies and culture of the organism. However, because most type
of cutaneous tuberculosis are
paucibacillary, it is often difficult to demonstrate or grow the
organism from the skin. Over the last few years, some reports have documented the use of
PCR in identifying M. tuberculosis DNA in lesions of cutaneous tuberculosis. However, the
test has not been prospectively evaluated in the diagnosis of the disease. We performed PCR
using primers and probes based on the published sequence of immunogenic protein MPB64,
a gene unique to the M. tuberculosis complex. The test was performed in 64 cases and 45
controls. For the purposes of this study, cases were defined as patients who had all of the
following: skin lesions morphologically suggestive of cutaneous tuberculosis, a positive
Mantoux test, skin biopsy showing granulomatous dermatitis and a clinical response to
standard anti-tubercular therapy. Controls were defined as those patients who showed clinical
and/or biopsy findings definitely indicative of a diagnosis other than cutaneous tuberculosis.
Eighteen out of 64 cases and 11 out of 45 controls showed a positive result on PCR. Thus,
the test had a
sensitivity of 28.1% a specificity of 75.6% and a likelihood ratio of a
positive
result of 1:1. PCR for
cutaneous tuberculosis does not appear to be a useful test in our hands.
The
search for a reliable diagnostic test for cutaneous tuberculosis must continue.
B. Clinical evaluation of the efficacy and safety of topical butenafine in comparison with topical
clotrimazole in tines cruris and tines
corporis (Microbiology, Laboratory Medicine).
Butenafine hydrochloride is a new
benzylamine derivative which has primary fungicidal activity
against dermatophytes.
We evaluated the
efficacy and safety of butenafine in comparison with
topical clotrimazole in
the treatment of tinea cruris and tinea corporis in patients attending the
skin
OPD at our hospital during the study period (February to December 2000). All patients
who fulfilled the inclusion
criteria for the study were randomly allocated to treatment with butenafine
once daily for 2 weeks or clotrimazole twice daily for 4 weeks in a double
blind manner.
Clinical examination and
microscopy of potassium hydroxide preparations of scrapings and
culture for
dermatophytes were conducted at baseline and at 1 week, 2 weeks, 4 weeks, 6
weeks
and 8 weeks following initiation of therapy. Efficacy was evaluated by the presence of mycological
and clinical cure. Adverse reactions, if any, were recorded at each visit. Seventy-five patients
were enrolled into the study, 37 were in the butenafine group and 38 in the clotrimazole group.
Fourteen patients in the butenafine group and nine in the
clotrimazole group were lost to follow-up
.
The sign and symptom score declined significantly in both the
groups. At the end of 8 week the
number
of patients showing mycologic cure (on KOH preparation) in the butenafine and
clotrimazole
treatment groups was 20/22 patients and 27/28 patients respectively. Three patients in each group
showed relapses after treatment cessation. Butenafine 1% cream is as effective as topically
applied clotrimazole 1% cream in the treatment of tinea cruris and corporis with the advantage
of once-daily application and
shorter duration of treatment.
C.
A two-step schedule for the treatment of actinomycotic
mycetomas (Microbiology)
Actinomycotic mycetomas usually respond slowly to treatment with antibiotics. In an attempt to
hasten clinical resolution, we used a 2-step regimen consisting of
an intensive phase of therapy
with penicillin, gentamicin and co-trimoxazole
for 5-7 weeks followed by maintenance therapy with amoxycillin and
co-trimoxazole. Seven patients were
treated, all of whom showed significant
reduction in discharge and swelling after the intensive phase. Maintenance therapy was continued
until the lesions completely healed clinically and upto 6
months beyond that maintenance therapy
was given for 6-16 months (mean 10.7
months), and patients remained free of
disease during a
mean post-treatment follow up of 6-4 months. The other 2
patients have also responded
satisfactorily and continue to receive maintenance
therapy. Side effects necessitating a
modification of the treatment schedule occurred in 2 patients but reversed on
stopping the
responsible drugs. This treatment schedule produces a rapid
clinical response during the initial intensive phase and promotes compliance
with the longer maintenance phase of treatment necessary to achieve a complete
cure.
A. Dermatological complications in renal transplant recipient patients - A follow up study of 500
patients (Department of
Nephrology).
B. Role of electron beam radiation therapy for the treatment of mycosis fungoides (Department of
Radiation
Oncology).
1. Sharma VK. Patch testing with European standard series and compositae extracts in patients
with air borne contact
dermatitis. Contact Dermatitis 2001:44:49-50.
2. Penchalaiah S, Handa S, Bijaya Lakshmi, Sharma VK, Kumar B. Sensitizers commonly causing
allergic
contact dermatitis from cosmetics. Contact Dermatitis 2000; 43:311-312.
3.
Sharma VK, Sahoo B.
Prurigo-nodularis like lesion in parthenium dermatitis. Contact Dermatitis 2000;42 (4):235.
4.
Sood A, Sharma S, Sharma VK. Morphoea with mucin deposits masquerading as
scleromyxoedema. Indian J Dermatol
Venereol Leprol 2000;66:109.
5.
Vatve M, Sharma VK, Sawhney IMS, Kumar B. Evaluation of patch test in identification
of causative agent in drug rashes due to antiepileptics. Indian J Dermatol
Venereol Leprol 2000; 66:132-135.
6.
Sharma VK, Prasad HRY. Management of Androgenic
Alopecia. Indian J Dermatol
2000:45:54-61.
7.
Sharma N, Sharma VK,
Gupta A, Kaur I, Ganguly VK.
Immunological defect in leprosy patient altered T-lymphocyte
signals. FEMS Immunol Microbiol. 1999;
23 (4):355-62.
8.
Sarkar R, Kaur I, Das
A, Sharma VK. Macular lesions in
leprosy: a clinical, bacteriological and histopathological study. J Dermatol. 1999 26(9):569-76.
9.
Gupta A, Sharma VK,
Vohra H, Ganguly NK. Inhibition of
apoptosis by ionomycin and zinc in peripheral blood mononuclear cells (PBMC) of
leprosy patients. Clin Exp Immunol. 1999 117 (1):56-62.
10.
Srinivasan S, Nehru VI,
Bapuraj JR, Sharma VK, Mann SB. CT
findings in involvement of the paranasal sinususes by lepromatous leprosy. Br J Radiol. 1999; 72(855):271-3.
11.
Gupta A, Sharma VK,
Vohra H, Ganguly NK. Spontaneous
apoptosis in peripheral blood mononuclear cells of leprosy patients: role of
cytokines. Immunol Med Microbiol. 1999 24(1):49-55.
12.
Soni A, Mittal BR, Kaur
I, Sharma VK, Pathak CM, Kumar B. Bone scintigraphy in leprosy. Int J Lepr
1998; 66(4):483-4.
13. Sirka CS, Ramam M, Mital R,
Khaitan BK, Verma KK. Olmsted
syndrome. Indian J Dermatol Venereol
Leprol 1999; 65:237-239.
14.
Ramam M, Manchanda Y,
Verma KK, Sharma VK. Reproducibility of
titre of contact hypersensitivity to Parthenium hysterophorus. Contact Dermatitis 2000; 42:366.
15.
Ramam M, Garg T, D’Souza P, Verma KK, Khaitan BK, Singh MK,
Banerjee U. A two-step schedule for the treatment of actinomycotic
mycetomas. Acta Derma-Venereol, 2000;
80:378-380.
16.
Verma KK, Lalhanpal S, Sirka CS, Khaitan BK, Ramam M,
Banerjee U. Primary cutaneous
actinomycosis. Acta
Derm-Venereol,1999;78:327.
17.
Grover JK, Vats V, Gopalakrishna R, Ramam M. Thalidomide: a relook. Natl Med J india
2000; 13:132-141.
18.
Sharma VK, Achar A, Ramam M, Singh MK. Multiple cutaneous horns overlying lichen
planus hypertrophicus. Br J Dermatol 2001; 144:424-425.
19.
Ramam M, D’Souza P, Ravindraprasad JS, Iyer KV, Singh
MK. Mycosis fungoides treated with PUVA
and topical corticosteroids. Ind J
Dermatol Venereol Leprol 2000;66:251-253.
20.
Ramam M, Kumrah L.
Systemic corticosteroid therapy and the hypothalamo-pituitary adrenal
axis. Ind, J. of Dermatol, 2001;
46:1-7.
21.
Verma KK, Mittal R, Manchanda Y Khaitan BK : Lichen planus
treated with betamethasone oral mini pulse therapy. Indian J Dermatol Venereol Leprol 2000; 66: 34-35.
22.
Verma KK, Rathi S,
Pasricha JS: Failure of pentoxifylline to affect airborne contact dermatitis
caused by Parthenium. Ind J Dermatol Venereol Leprol 2000; 66: 129-131.
23.
Verma KK, Lakhanpal S,
Sirka CS, Khaitan BK, Banerjee U: Disseminated
mucocutaneous blastomycosis in
an immunocompetant Indian patient
treated with ketoconazole. J
Euro Acad Dermatol Venereol 2000; 14:
332-333.
24.
Verma KK, Parida DK,
Rath GK: Cutaneous T-cell lymphoma treated with electron beam radiation -
Indian experience. J Euro Acad Dermatol Venereol 2000; 14 (suppl 1): W 41
(Abst).
25.
Verma K and Verma KK:
Infantile periocular haemangioma treated with betamethasone oral mini pulse
therapy. Ind J Ped 2001; 68: 367-368.
26.
Khaitan BK, Mittal R, Ramam M, Jain Y. Flexural keratoderma,
recurrent purpura, gastroenteritis and respiratory tract infection. Indian J
Pediatr Dermatol, 2000; 3: 23-24.
27.
Sood A, Khaitan BK,
Khanna NK, Kumar R, Singh MK. Syringocystadernoma papilliferum at unusual
sites. Indian J Dermatol Venereol Leprol
2000; 66:328-329.
1.
Sharma VK, Treatment of Cutaneous tuberculosis and
Mycobacterial Infections. In, Workbook
of 4th National CME on Dermato Pathology, New Delhi, 2000.
2.
Sharma VK: Treatment of Difficult Psoriasis, In, Dermatology
Update-2000, Edited by Col. S.K. Sayal, Base Hospital, Delhi Cantt.
3.
Ramam M, Satish D, Thomas J, Parikh DA, Skin diseases in children, In:Parthasarathy A, Menon
PSN, Nair MKC, Lokeshwar MR, Srivastava RN, Bhave SY et al, Editors, IAP
Textbook of Pediatrics New Delhi, 1999, p 814-820.
4.
Ramam M. Cutaneous
tuberculosis. In: Sharma SK, Mohan A,
Editors, Tuberculosis, New Delhi, Jaypee brothers Medical Publishers (P) Ltd.,
2001, P 261-272.
5.
Ramam M, Gupta LK, Dermatologic Emergencies in Children. In:
Singh M, Editor, Medical Emergencies in Children, 3rd edition, New
Delhi, 2000, p 587-601.
6.
Khaitan BK, Mittal R. “Role of vitamin E as an antioxidant
in Dermatology.
In, Sacchinand S, Editor, “Role of
Antioxidants in Dermatology” published by 28th National conference
of IADVL, 2000: 57-60.
7.
Khaitan BK. Pulse Therapy in Dermatology
In, ‘Dermatology Update-2000’
Edited by Col. S.K. Sayal, Base Hospital, Delhi Cantt.
8.
Khaitan BK, Dattagupta, S, D’Souja P. Fungal Infections
In, Workbook of 4th National
CME on Dermatopathology, New Delhi, 2000.
9. Current Literature Dermatology 1999-2000.
Pasricha JS,
Misra RS, Ramesh V, Ramam M, Khaitan BK et al.
IADVL (Delhi State Branch), New Delhi.
10. Verma KK and Singh MK: Vesiculobullous Disorders, in
Work-book - 4th National CME on Dermatopathology, AIIMS, New Delhi, 2001;
p 1-6.
1
Indo US workshop on Sexually Transmitted Diseases and
Reproductive Tract Infections, New Delhi (Nov. 8-10,2000) in colloboration with
Department of Biotechnology & Department of Pathology.
2. 4th National CME on
Dermatopathology in collaboration with Department of pathology on Feb. 24=25th, 2001.
4.
Prof. V.K. Sharma received Indian Council of Medical
Research “Lala Ram Chand Kandhari” award for Dermatology and Sexually
Transmitted Diseases.
5.
Prof. V.K. Sharma served as President, Indian Association of
Dermatologists, Venereologists &
Leprologists(Delhi State Branch) for the Year 2000 and Honorary Secretary –
Contact and Occupational Dermatoses Forum of India (CODFI) for the year 2000.
6.
Dr. B.K. Khaitan served as Vice-President, Indian
Association of Dermatologists, Venereologists & Lepropolgists (DSB) for the
year 2000.
7.
Dr. K.K. Verma served as Honorary Secretary – Indian
Association of Dermatologists, Venereologists and Leprologists (DSB) for the
year 2000.